You're contacting media contact of this press release

Title: CoreAge Rx Debuts Spot On Prescription Treatment to Target Stubborn Dark Spots and Hyperpigmentation

Wichita Falls, TX, United States, 30th Jul 2026 - Telehealth provider CoreAge Rx today announced the launch of Spot On, a prescription-strength topical formulation specifically engineered to address hyperpigmentation, sun damage, and post-inflammatory marks. Designed as a localized corrective treatment, the new addition to the CoreAge Rx dermatology portfolio provides a direct approach for individuals seeking to achieve a clearer, more even skin tone.At the center of the Spot On formulation is Hydroquinone, a clinically proven depigmenting agent that works directly on hyperpigmented areas to lighten dark spots. To reinforce the brightening process, the compound includes Kojic Acid, which helps inhibit melanin production and restore skin clarity. Niacinamide completes the active blend by soothing localized inflammation, reinforcing the skin’s moisture barrier, and enhancing overall skin texture.Unlike general facial creams, Spot On is formulated strictly for spot application on hyperpigmented areas. Patients apply a small amount to clean, dry skin as directed by their healthcare provider. Due to the high potency of its active ingredients, clinicians typically recommend using the treatment for targeted intervals rather than continuous long-term application. Daily broad-spectrum sunscreen use and sun avoidance are strongly emphasized during the treatment period to prevent recurring discoloration.Patients can request access to Spot On through the CoreAge Rx digital platform via a completely remote consultation process. After completing a secure online health questionnaire, the submission is evaluated by a US board-certified physician. Upon clinical approval, the tailored prescription is compounded in an American pharmacy and delivered directly to the patient's residence. Co...

This press release is issued by King Newswire